newsfilter
← Earnings
Earnings Releases·

Adagio Medical — Third Quarter 2026 Earnings Summary

Adagio Medical Holdings reported a net income of $17.8 million for the third quarter of 2026, driven primarily by a $23.0 million noncash gain from the change in fair value of its convertible notes. The company treated 22 patients with its vCLAS Ultra System in the United States and Canada, including 19 in the FULCRUM-VT IDE sub-study, while initiating a formal process to explore strategic alternatives. Research and development expenses decreased to $1.8 million, and selling, general, and administrative expenses fell to $2.6 million compared to the prior year period. On November 6, 2026, the company completed a one-for-thirty reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Company
ADAGIO MEDICAL HOLDINGS INC
Sector
Healthcare
Industry
Medical Devices